Myriad Genetics (MYGN) Stock Rating Reaffirmed by Barclays

Myriad Genetics (NASDAQ:MYGN)‘s stock had its “hold” rating reiterated by investment analysts at Barclays in a report released on Monday. They presently have a $30.00 target price on the stock. Barclays’ target price points to a potential downside of 13.44% from the company’s current price.

Several other research analysts have also commented on MYGN. Cowen restated a “hold” rating and issued a $25.00 price objective on shares of Myriad Genetics in a report on Sunday, September 17th. Stephens restated an “overweight” rating and issued a $40.00 price objective (up from $36.00) on shares of Myriad Genetics in a report on Friday, September 22nd. Leerink Swann restated a “market perform” rating and issued a $31.00 price objective on shares of Myriad Genetics in a report on Monday, October 2nd. Morgan Stanley restated an “underweight” rating and issued a $24.00 price objective (up from $17.00) on shares of Myriad Genetics in a report on Friday, October 6th. Finally, Zacks Investment Research upgraded shares of Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price objective for the company in a report on Tuesday, October 17th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $30.09.

Shares of Myriad Genetics (MYGN) traded up $0.92 during midday trading on Monday, reaching $34.66. 700,300 shares of the company’s stock traded hands, compared to its average volume of 514,100. The company has a quick ratio of 2.06, a current ratio of 2.34 and a debt-to-equity ratio of 0.09. Myriad Genetics has a 1-year low of $15.15 and a 1-year high of $37.30. The company has a market cap of $2,370.00, a price-to-earnings ratio of 23.42, a PEG ratio of 2.21 and a beta of 0.24.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.05. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The business had revenue of $190.20 million during the quarter, compared to analyst estimates of $183.52 million. During the same period in the prior year, the business earned $0.23 EPS. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. research analysts expect that Myriad Genetics will post 1.05 EPS for the current year.

In other news, Director Heinrich Dreismann sold 6,000 shares of the company’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $33.50, for a total value of $201,000.00. Following the sale, the director now directly owns 33,743 shares of the company’s stock, valued at approximately $1,130,390.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Walter Phd Gilbert sold 7,500 shares of the stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $33.19, for a total transaction of $248,925.00. The disclosure for this sale can be found here. Insiders sold a total of 16,531 shares of company stock worth $545,826 over the last ninety days. Insiders own 6.70% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in Myriad Genetics during the 2nd quarter valued at about $101,000. Riverhead Capital Management LLC grew its position in Myriad Genetics by 80.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock valued at $107,000 after purchasing an additional 1,861 shares during the last quarter. Fiduciary Trust Co. purchased a new stake in Myriad Genetics during the 2nd quarter valued at about $113,000. Meeder Asset Management Inc. grew its position in Myriad Genetics by 1,067.4% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,292 shares of the company’s stock valued at $119,000 after purchasing an additional 3,010 shares during the last quarter. Finally, Tiedemann Wealth Management LLC grew its position in Myriad Genetics by 67.0% during the 3rd quarter. Tiedemann Wealth Management LLC now owns 13,650 shares of the company’s stock valued at $185,000 after purchasing an additional 5,475 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: “Myriad Genetics (MYGN) Stock Rating Reaffirmed by Barclays” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/10/myriad-genetics-mygn-stock-rating-reaffirmed-by-barclays.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply